Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Industry Satellite Symposia webcasts


Watch the webcasts from our industry partners' Satellite Symposia.

30 Mar 2023

Daiichi Sankyo and AstraZeneca
Addressing the unmet need in mNSCLC: Treating progression after immunochemotherapy   

Watch session

  • Welcome and introduction
    M. Perol
  • Strategies for treating patients with progression after immunochemotherapy
    M. Perol
  • Antibody-drug conjugates: Current perspectives
    A. Passaro
  • Antibody-drug conjugates: Future considerations
    E. Felip
  • Audience Q&A and closing remarks
    M. Perol

Janssen Pharmaceuticals
Exploring clinical perspectives in advanced EGFR-mutant NSCLC: How far we have come   

Watch session

  • Welcome and introduction
    Alfredo Addeo
  • Translating data into clinical practice in EGFR-mutant NSCLC
    Zopia Piotrowska
  • Practical data applications in EGFR exon20ins-mutant NSCLC
    Nicolas Girard
  • Q&A and closing remarks
    Enriqueta Felip

31 Mar 2023

Latest scientific advances and investigational approaches with IO in NSCLC

Watch session

  • Introduction
    D. Planchard
  • The latest in checkpoint inhibition
    N. Leighl
  • Advances in novel IO combinations
    N. Reinmuth
  • Ongoing IO trials & potential implications
    D. Planchard
  • Panel Discussion and Q&A
    D. Planchard

Novocure GmbH
The evolving role of tumor treating fields therapy in thoracic oncology

Watch session

  • Welcome and introduction
    Corey Langer
  • The practice-changing experience with TTFields therapy in glioblastoma
    Andreas Hottinger
  • The expanding experience with TTFields therapy in pleural mesothelioma
    Federica Grosso
  • Is there a place for TTFields therapy in non-small cell lung cancer?
    Corey Langer
  • Panel discussion: Evolving role of TTFields therapy in solid tumors
    Andreas Hottinger
  • Concluding remarks and close
    Corey Langer

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.